[go: up one dir, main page]

AR114075A1 - Composiciones y métodos para modular el crecimiento del cabello - Google Patents

Composiciones y métodos para modular el crecimiento del cabello

Info

Publication number
AR114075A1
AR114075A1 ARP190100011A ARP190100011A AR114075A1 AR 114075 A1 AR114075 A1 AR 114075A1 AR P190100011 A ARP190100011 A AR P190100011A AR P190100011 A ARP190100011 A AR P190100011A AR 114075 A1 AR114075 A1 AR 114075A1
Authority
AR
Argentina
Prior art keywords
hair growth
alkyl
halo
carboxyl
methods
Prior art date
Application number
ARP190100011A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of AR114075A1 publication Critical patent/AR114075A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente divulgación se refiere a compuestos que son capaces de inhibir el vehículo de piruvato mitocondrial y promover el crecimiento capilar. La divulgación se refiere adicionalmente a métodos para promover el crecimiento capilar o tratar afecciones o trastornos que afectan al crecimiento capilar, tales como calvicie o alopecia. Reivindicación 1: Un compuesto de fórmula (1) ó (2), en donde: cada A es independientemente CH, CR⁴, o N; Y es carboxilo, éster, amida o un resto de fórmula (3); Z es CH, CR⁴, o N; R² es CN o carboxilo; R³ es H, arilo, aralquilo o aralquilacilo, y está opcionalmente sustituido con uno o más R⁵, en donde cada R⁵ se selecciona independientemente de alquilo, alcoxi o halo; cada caso de R⁴ es independientemente alquilo, carboxilo, halo, hidroxi, éster o CN; R⁷ es hidrógeno, alquilo, halo, hidroxilo, alcoxi o aciloxi; R¹⁰ es hidrógeno o alquilo; y n es 0 - 4; o una sal farmacéuticamente aceptable de los mismos.
ARP190100011A 2017-06-30 2019-01-03 Composiciones y métodos para modular el crecimiento del cabello AR114075A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527775P 2017-06-30 2017-06-30
US201862654095P 2018-04-06 2018-04-06

Publications (1)

Publication Number Publication Date
AR114075A1 true AR114075A1 (es) 2020-07-15

Family

ID=64742233

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100011A AR114075A1 (es) 2017-06-30 2019-01-03 Composiciones y métodos para modular el crecimiento del cabello

Country Status (15)

Country Link
US (5) US11312714B2 (es)
EP (1) EP3644989A4 (es)
JP (3) JP7221227B2 (es)
KR (3) KR102872871B1 (es)
CN (2) CN116120314A (es)
AR (1) AR114075A1 (es)
AU (3) AU2018294351B2 (es)
CA (1) CA3067746A1 (es)
CL (1) CL2019003886A1 (es)
EA (1) EA202090179A1 (es)
IL (3) IL271443B2 (es)
MX (2) MX2019015475A (es)
PE (1) PE20200743A1 (es)
PH (1) PH12019502776A1 (es)
WO (1) WO2019006359A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213513B2 (en) 2017-02-24 2022-01-04 The Regents Of The University Of California Compositions and methods for promoting hair growth with Mpc1 inhibitors
PH12019502776A1 (en) 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
KR102767779B1 (ko) * 2018-04-13 2025-02-13 노쓰 캐롤라이나 스테이트 유니버시티 모발 성장 촉진을 위한 마이크로니들 패치의 사용
IL284397B2 (en) * 2019-01-02 2025-11-01 Univ California Compositions and methods for regulating hair growth
FR3105222B1 (fr) * 2019-12-20 2022-06-03 Nunii Laboratoire Inhibiteur du transporteur MCT7/SLC16A6 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur
AU2020407122A1 (en) * 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
US20230227406A1 (en) * 2020-06-12 2023-07-20 Rekindle Therapeutics Inc. Modulators of e3 ligases
US20230322765A1 (en) * 2020-06-30 2023-10-12 The Regents Of The University Of California Compositions and methods for modulating hair growth
US20240327400A1 (en) * 2020-06-30 2024-10-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
CN118843627A (zh) * 2021-12-29 2024-10-25 皮乐吉制药公司 用于治疗脱发的化合物
EP4457226A1 (en) 2021-12-29 2024-11-06 Pelage Pharmaceuticals, Inc. Compounds for treatment of hair loss
WO2023191515A1 (ko) * 2022-03-29 2023-10-05 연세대학교 산학협력단 인디루빈 유도체 및 대사활성화제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR20250123928A (ko) * 2022-12-27 2025-08-18 펠라지 파마슈티컬스, 인크. 탈모 치료용 화합물
CN116251086A (zh) * 2023-02-15 2023-06-13 江西中医药大学 乳酸及其衍生物在促毛发生长及缓解脱发中的应用
CN121005682A (zh) * 2024-05-24 2025-11-25 上海医药工业研究院有限公司 一种2-苯基-吡咯类化合物、其制备方法及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPH0235746B2 (ja) 1983-03-07 1990-08-13 Sagami Chem Res 33chikantetorafuruoroindoorujudotai
US4680413A (en) * 1986-01-17 1987-07-14 Nippon Soda Co., Ltd. Process for the production of 3-phenyl-4-cyanopyrroles
GB8913708D0 (en) * 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
GB9023585D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
FR2796274B1 (fr) * 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
EP1267850B1 (en) 2000-02-23 2007-04-11 Orentreich Foundation for the Advancement of Science, Inc. Use of insulin sensitivity increasing substances for the treatment of alopecia
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
ES2300460T3 (es) 2001-07-17 2008-06-16 N-Gene Research Laboratories Inc. Combinaciones farmaceuticas sinergicas destinadas a la prevencion o al tratamiento de la diabetes.
WO2004080481A1 (en) * 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
JP2007512263A (ja) 2003-11-25 2007-05-17 ノボ　ノルディスク　アクティーゼルスカブ 化学的脱共役剤として使用するためのインドール誘導体
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US20050277784A1 (en) 2004-06-14 2005-12-15 Wyeth Processes for the preparation of 2-cyano-3-naphthalene-1-yl-acrylic acid alkyl or benzyl esters
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
ES2614113T3 (es) 2004-09-17 2017-05-29 Biomas Ltd. Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
EP1919449A2 (en) 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
CL2007002516A1 (es) 2006-08-31 2008-05-16 Smithkline Beecham Corp Compuestos derivados de indol indano; composicion farmaceutica; y su uso para tratar hiperglicemia, diabetes tipo 2, tolerancia deteriorada a la glucosa, resistencia a la insulina, sindrome x, dislipidemia.
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009030257A1 (en) 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
BRPI0819219B1 (pt) 2007-11-05 2021-09-21 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Derivados de 7-azaindol como inibidores de 11-beta-hidroxiesteroide desidrogenase tipo 1 seletivos, seu uso e seu método de preparação, composição farmacêutica e seu processo de fabricação, e kit
TWI461423B (zh) * 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
US20130023587A1 (en) 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
ES2630309T3 (es) 2011-12-22 2017-08-21 Connexios Life Sciences Pvt. Ltd. Derivados de amigos cíclicos como inhibidores de la 11-beta-hidroxisteroide deshidrogenasa y usos de los mismos
EP2847356A4 (en) 2012-05-10 2015-08-05 Univ Utah Res Found COMPOSITIONS AND METHOD FOR MODULATING MITOCHONDRIAL PYRUVATE CARBON ACTIVITY
WO2013185214A1 (en) 2012-06-11 2013-12-19 Universite Laval Pla2g7/lp-pla2 as biomarker and therapeutic target in the prevention and treatment of calcific aortic valve disease
US9452959B2 (en) 2012-06-12 2016-09-27 The Regents Of The University Of California Fluorination of aryl compounds
WO2014113467A1 (en) 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
JP2016530209A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ビニルオートタキシン阻害剤化合物
US20160250249A1 (en) * 2013-10-03 2016-09-01 Inserm ( Institute National De Lasanté Et De La Re Cherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP3096761A1 (en) 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
EP3455207A4 (en) 2016-05-12 2019-10-09 Regents of the University of Minnesota INDOL AND INDAZOCYANOCINNAMATE COMPOUNDS AND THERAPEUTIC USES THEREOF
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
EP3503871B1 (en) * 2016-08-26 2021-11-17 The Regents of The University of California Hair follicle stem cell activation and hair growth
US20200085828A1 (en) 2016-12-22 2020-03-19 Mavupharma, Inc. Phosphodiesterase inhibitors and methods of microbial treatment
US11213513B2 (en) 2017-02-24 2022-01-04 The Regents Of The University Of California Compositions and methods for promoting hair growth with Mpc1 inhibitors
CN106880693A (zh) 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法
PH12019502776A1 (en) 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
SG10202109849SA (en) 2017-09-29 2021-10-28 Univ California Compositions and methods for modulating hair growth
IL284397B2 (en) 2019-01-02 2025-11-01 Univ California Compositions and methods for regulating hair growth
US20220079899A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating ocular conditions
US20220079900A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating cardiac injury
AU2020407122A1 (en) 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
US20240327400A1 (en) 2020-06-30 2024-10-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
US20230322765A1 (en) 2020-06-30 2023-10-12 The Regents Of The University Of California Compositions and methods for modulating hair growth

Also Published As

Publication number Publication date
US11312714B2 (en) 2022-04-26
KR20240033119A (ko) 2024-03-12
US20200157093A1 (en) 2020-05-21
JP2023061995A (ja) 2023-05-02
AU2018294351B2 (en) 2022-12-22
US20230114220A1 (en) 2023-04-13
KR20250151619A (ko) 2025-10-21
US20250304579A1 (en) 2025-10-02
CN110944634A (zh) 2020-03-31
AU2023201669A1 (en) 2023-04-13
JP7221227B2 (ja) 2023-02-13
US20240025895A1 (en) 2024-01-25
MX2022007823A (es) 2022-07-19
CN116120314A (zh) 2023-05-16
IL321754A (en) 2025-08-01
EP3644989A4 (en) 2021-07-14
AU2025202961A1 (en) 2025-05-15
KR102642823B1 (ko) 2024-03-04
BR112019026080A8 (pt) 2022-11-22
KR102872871B1 (ko) 2025-10-16
EA202090179A1 (ru) 2020-04-24
US11787804B2 (en) 2023-10-17
CL2019003886A1 (es) 2020-05-22
NZ759233A (en) 2023-08-25
IL271443A (en) 2020-01-30
US20220153738A1 (en) 2022-05-19
JP2020526484A (ja) 2020-08-31
IL271443B2 (en) 2024-01-01
CA3067746A1 (en) 2019-01-03
IL305317B1 (en) 2025-07-01
US11472804B2 (en) 2022-10-18
AU2018294351A1 (en) 2019-12-05
PE20200743A1 (es) 2020-07-24
EP3644989A1 (en) 2020-05-06
WO2019006359A1 (en) 2019-01-03
IL305317B2 (en) 2025-11-01
MX2019015475A (es) 2020-02-19
KR20200022480A (ko) 2020-03-03
JP2025102814A (ja) 2025-07-08
PH12019502776A1 (en) 2020-10-26
AU2023201669B2 (en) 2025-01-30
IL271443B1 (en) 2023-09-01
BR112019026080A2 (pt) 2020-06-30
US12227503B2 (en) 2025-02-18
IL305317A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
AR114075A1 (es) Composiciones y métodos para modular el crecimiento del cabello
AR117555A1 (es) Composiciones y métodos para modular el crecimiento del cabello
PE20251291A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
MX2024015363A (es) Compuestos de haloalquinilo para el tratamiento de cáncer
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
AR120109A1 (es) Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR107616A1 (es) Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
ES2722409T3 (es) Moduladores de ROR gamma (RORy)
AR091490A1 (es) Antagonistas de iap
ECSP10010405A (es) Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico
AR094647A1 (es) Análogos de 7,8-morfinano cíclico
PE20240017A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR064760A1 (es) Derivados de diazol como inhibidores de la eg-5
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
PE20221732A1 (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2018010787A2 (es) Compuesto de griseofulvina
CO2025018750A2 (es) Inhibidores de wrn
AR054272A1 (es) Derivados de 3- aminopirrilidinas tri, tetra - sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal